Onteis is developing a platform to produce non-cytotoxic treatments aimed at cancer normalization. Cancer normalization leads to the anatomical and functional reconstruction of cancerous tissues and their reintegration into the organism. This approach represents a new class of therapies designed to improve the therapeutic index (efficacy/toxicity) compared to conventional cytotoxic treatments. By avoiding cell destruction, Onteis' future treatments aim to enhance tolerance while restoring the normal function of affected tissues.